Related Experiment Video

Updated: Feb 4, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?

Carolyne Ghobrial1, Rodina Sobhy2, Engy Mogahed1

  • 1The Pediatric Hepatology Unit, Cairo University, Egypt.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|October 15, 2018
PubMed

Insights

Sofosbuvir/ledipasvir treatment for chronic hepatitis C in children showed no cardiovascular adverse events. This study found no symptomatic bradycardia or bradyarrhythmias in pediatric patients.

Area of Science:

  • Pediatric Cardiology
  • Hepatology
  • Pharmacology

Background:

  • Symptomatic bradycardia is a known risk in adults treated for chronic hepatitis C with sofosbuvir-based regimens.
  • Assessing cardiac safety in pediatric populations is crucial due to potential differences in drug response.

Purpose of the Study:

  • To evaluate the cardiac safety of sofosbuvir/ledipasvir in Egyptian children and adolescents with chronic hepatitis C.
  • To monitor electrocardiographic parameters during antiviral therapy.

Main Methods:

  • A cohort of 40 children and adolescents (12-17 years) with chronic hepatitis C received sofosbuvir/ledipasvir (Harvoni) daily for 12 weeks.
  • Standard 12-lead surface electrocardiography (ECG) was performed at baseline, 4 weeks, and 12 weeks.
  • Key ECG parameters including heart rate, RR interval, and QT interval were analyzed and compared across time points.

Main Results:

  • No cardiovascular symptoms or adverse events, including symptomatic bradycardia or syncope, were reported during treatment.
  • A significant decrease in heart rate and significant prolongation of RR and QT intervals were observed at baseline compared to therapy.
  • Lower heart rate and longer RR intervals were noted in patients with higher viral loads.

Conclusions:

  • Sofosbuvir/ledipasvir demonstrated a favorable cardiovascular safety profile in pediatric patients with chronic hepatitis C.
  • No bradyarrhythmias were observed, indicating safety in this specific pediatric cohort.
Abstract

Keywords:
BradycardiaECGHCVSofosbuvir

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
128.2K
Guidelines and Strategies for Safe Computer Charting01:18

Guidelines and Strategies for Safe Computer Charting

The guidelines and strategies provided by the American Nurses Association (ANA) and the Canadian Nurses Association (CNA) offer essential principles for ensuring safe and secure computer charting systems in healthcare settings. Let's break down each recommendation:
Maintain Confidentiality and Security:
2.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Anatomy of the Heart01:27

Anatomy of the Heart

The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
119.8K
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244